| July 01, 2009 |
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa| --Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study
AMSTERDAM, July 1, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corp., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant fol... |
|
 |
| June 29, 2009 |
Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings| KENILWORTH, N.J., June 29 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) is scheduled to announce its sales and earnings
results for the 2009 second quarter on Tuesday, July 21, 2009.
At approximately 7:45 a.m. (EDT) on that day, Schering-Plough will conduct
a conference call to review results for the 2009 second quarter. Fred Hassan,
Schering-Plough's chairman and CEO, and other members of management will host
the conference call.
To listen live to the cal... |
|
|
| June 26, 2009 |
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis| --Positive Opinion Recommends Approval of New Anti-TNF Therapy in Three Rheumatic Diseases with Novel SmartJect(TM) Autoinjector
HORSHAM, Pa. and KENILWORTH, N.J., June 26, 2009 /PRNewswire-FirstCall via COMTEX/ -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending the approval of SIMPONI(TM) (golimumab) as a once-m... |
|
|
| June 23, 2009 |
New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus| --Vaccine Against Canine Flu Granted Conditional License by USDA
ROSELAND, N.J., June 23, 2009 /PRNewswire via COMTEX/ -- Intervet/Schering-Plough Animal Health, the global leader in veterinary biologicals, today announced the availability of the first vaccine against canine influenza virus (CIV), which was granted a conditional product license by the U.S. Department of Agriculture (USDA) on May 27, 2009, for use by veterinarians in the United States. (http://www.aphis.usda.gov/newsroom/conte... |
|
|
| June 23, 2009 |
Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock| KENILWORTH, N.J., June 23, 2009 /PRNewswire-FirstCall via COMTEX/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 31, 2009, to shareholders of record at the close of business on August 7, 2009. As of March 31, 2009, there were 1,628,335,093 common shares outstanding.
The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convert... |
|
|
| June 22, 2009 |
Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jun. 22, 2009--
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:
SGP) today announced that they each have received a request for
additional information from the U.S. Federal Trade Commission (FTC) with
respect to their previously announced proposed merger. The request for
information from the FTC, often referred to as a “second request,” was
anticipated as part of the r... |
|
|
| June 17, 2009 |
The New York Yankees' Mark Teixeira, National Foundation For Cancer Research, and the Makers of COPPERTONE SPORT(R) Launch 'Help Strike Out Sun Damage' Program| Program Asks Athletes and Fans Alike to Educate and Protect Themselves
against Incidental Sun Damage
KENILWORTH, N.J., June 17 /PRNewswire-FirstCall/ -- With the first day of
summer around the corner, Schering-Plough Corporation (NYSE: SGP), the makers
of COPPERTONE(R), announced today that they have teamed up with New York
Yankees' first baseman Mark Teixeira and the National Foundation for Cancer
Research (NFCR) for "Help Strike Out Sun Damage," a campaign to raise
awareness abo... |
|
|
